Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 169,698,192
  • Shares Outstanding, K 2,696,190
  • Annual Sales, $ 40,122 M
  • Annual Income, $ 2,394 M
  • 36-Month Beta 0.77
  • Price/Sales 4.20
  • Price/Cash Flow 10.94
  • Price/Book 4.97

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.80 +4.53%
on 06/27/18
63.04 -0.84%
on 07/13/18
+1.48 (+2.43%)
since 06/19/18
3-Month
56.26 +11.12%
on 05/08/18
63.04 -0.84%
on 07/13/18
+3.87 (+6.60%)
since 04/19/18
52-Week
52.83 +18.32%
on 04/03/18
66.41 -5.87%
on 09/18/17
-0.11 (-0.18%)
since 07/19/17

Most Recent Stories

More News
Roche's Tecentriq Met Primary Goal in First-Line NSCLC Study

Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS).

MRK : 62.51 (-0.68%)
NVS : 80.80 (-0.20%)
RHHBY : 28.9100 (-1.13%)
BMY : 56.54 (-0.60%)
Merck Reinforces Commitment to Responsible Pricing

Merck (NYSE:MRK), known as MSD outside the United States and Canada, has a long history of responsible pricing. In 2017, Merck issued its second annual Pricing Action Transparency Report,...

MRK : 62.51 (-0.68%)
J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales

J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it narrows its full year sales forecast due to currency factors.

JNJ : 125.94 (-1.46%)
MRK : 62.51 (-0.68%)
ABBV : 89.95 (-4.71%)
ALXN : 135.09 (-0.41%)
Does the $4.7 Billion Talc Verdict Spell Trouble for J&J?

Does the $4.7 Billion Talc Verdict Spell Trouble for J&J?

MRK : 62.51 (-0.68%)
JNJ : 125.94 (-1.46%)
Does the $4.7 Billion Talc Verdict Spell Trouble for J&J?

Does the $4.7 Billion Talc Verdict Spell Trouble for J&J?

MRK : 62.51 (-0.68%)
JNJ : 125.94 (-1.46%)
Adult Vaccine Market: Global Analysis by Disease & Companies to 2024 - Featuring Leading Players GlaxoSmithKline, Merck, Sanofi and Pfizer - ResearchAndMarkets.com

The "Adult Vaccine Market, Global Analysis By Disease (Influenza, Cervical Cancer, Zoster, MMR , Pneumonia, Meningitis, Hepatitis, Tap , Varicella & Travel & Miscellaneous Vaccine)...

MRK : 62.51 (-0.68%)
GSK : 40.69 (-0.68%)
Amgen Resubmits BLA to FDA for Osteoporosis Candidate Evenity

Amgen Inc. (AMGN) and its partner UCB announce the resubmission of the BLA to the FDA for Evenity to treat osteoporosis in postmenopausal women and in men at increased risk of fracture.

ESALY : 99.3550 (+1.67%)
MRK : 62.51 (-0.68%)
HLUYY : 70.1600 (+0.01%)
AMGN : 191.76 (-0.54%)
CCXI : 12.30 (-1.28%)
Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?

The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2

JNJ : 125.94 (-1.46%)
MRK : 62.51 (-0.68%)
ABBV : 89.95 (-4.71%)
HLUYY : 70.1600 (+0.01%)
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

CTIC : 2.27 (+0.44%)
AZN : 37.03 (-0.80%)
JNJ : 125.94 (-1.46%)
MRK : 62.51 (-0.68%)
ABBV : 89.95 (-4.71%)
PFE : 37.36 (-0.80%)
BMY : 56.54 (-0.60%)
Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize

The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.

MSFT : 104.40 (-0.68%)
AAPL : 191.88 (+0.78%)
CSCO : 42.40 (+0.45%)
CVX : 121.67 (+0.12%)
JPM : 109.89 (-1.47%)
INTC : 51.98 (+0.50%)
MRK : 62.51 (-0.68%)
CAT : 139.42 (-1.20%)
RDS.A : 69.17 (+0.39%)
PFE : 37.36 (-0.80%)
BP : 44.44 (+0.43%)
BA : 355.33 (-1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade MRK with:

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 63.26
1st Resistance Point 62.89
Last Price 62.51
1st Support Level 62.19
2nd Support Level 61.86

See More

52-Week High 66.41
Last Price 62.51
Fibonacci 61.8% 61.22
Fibonacci 50% 59.62
Fibonacci 38.2% 58.02
52-Week Low 52.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar